Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2023 - 2025)

Monte Rosa Therapeutics' Return on Capital Employed history spans 3 years, with the latest figure at 0.14% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 7.0% year-over-year to 0.14%; the TTM value through Dec 2025 reached 0.14%, down 7.0%, while the annual FY2025 figure was 0.14%, 7.0% down from the prior year.
  • Return on Capital Employed reached 0.14% in Q4 2025 per GLUE's latest filing, down from 0.22% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.24% in Q2 2025 to a low of 0.62% in Q4 2023.
  • Average Return on Capital Employed over 3 years is 0.2%, with a median of 0.14% recorded in 2025.
  • The largest YoY upside for Return on Capital Employed was 77bps in 2025 against a maximum downside of -7bps in 2025.
  • A 3-year view of Return on Capital Employed shows it stood at 0.62% in 2023, then soared by 89bps to 0.07% in 2024, then tumbled by -108bps to 0.14% in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Return on Capital Employed are 0.14% (Q4 2025), 0.22% (Q3 2025), and 0.24% (Q2 2025).